With our new knowledge into the underlying mechanism of PML function, the pharmacological targeting of FAO, or the use of PPAR inhibitors in combination with low doses of ATO might exert a synergistic effect on triple-negative breast cancer tumors and possibly other solid tumors or leukemias. The gene discussed is PML; the disease is triple-negative breast carcinoma.